Reactive oxygen species (ROS), produced by the NADPH oxidases family, NOX, is at the core of inflammation and ageing. The GREPI tries to work out the role of the NOXs and to identify the targets of the oxidizing radicals produced during pathophysiologic disorders. Among these targets, we emphasize on matrix metalloproteases.

Starting form the prototype NADPH oxidase of phagocytes and chronic granulomatose disease (CGD), a rare hereditary disorder resulting from null oxidase activity, we developed both fundamental and applied research. From these bases, cellular and animal models were built and characterized to unravel repair mechanisms and develop therapy such as vaccines, peptide inhibitors, monoclonal antibodies, protein medicines which will eventually be evaluated in human clinical applications.

These developments are based on innovative technologies in the field of the intracellular transfer of therapeutic proteins using the properties of bacterial type III secretion system, acellular proteoliposome synthesis, and the development of new peptide translocation domains (PTD).

http://www-sante.ujf-grenoble.fr/GREPI/Index.htm